vs
Side-by-side financial comparison of ENANTA PHARMACEUTICALS INC (ENTA) and FrontView REIT, Inc. (FVR). Click either name above to swap in a different company.
ENANTA PHARMACEUTICALS INC is the larger business by last-quarter revenue ($18.6M vs $16.5M, roughly 1.1× FrontView REIT, Inc.). FrontView REIT, Inc. runs the higher net margin — -24.9% vs -64.1%, a 39.2% gap on every dollar of revenue.
Enanta Pharmaceuticals Inc is a clinical-stage biotechnology company that develops innovative antiviral therapies for infectious diseases including hepatitis B virus, respiratory syncytial virus (RSV), and SARS-CoV-2. It operates primarily in the U.S. and global markets, partnering with pharmaceutical firms to advance its small molecule drug candidate pipeline for patients with unmet medical needs.
ENTA vs FVR — Head-to-Head
Income Statement — Q1 FY2026 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $18.6M | $16.5M |
| Net Profit | $-11.9M | $-4.1M |
| Gross Margin | — | — |
| Operating Margin | -60.5% | — |
| Net Margin | -64.1% | -24.9% |
| Revenue YoY | 9.8% | — |
| Net Profit YoY | 46.4% | — |
| EPS (diluted) | $-0.42 | $-0.19 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $18.6M | $16.5M | ||
| Q3 25 | $15.1M | $16.8M | ||
| Q2 25 | $18.3M | $17.6M | ||
| Q1 25 | $14.9M | $16.2M | ||
| Q4 24 | $17.0M | — | ||
| Q3 24 | $14.6M | $14.5M | ||
| Q2 24 | $18.0M | — | ||
| Q1 24 | $17.1M | — |
| Q4 25 | $-11.9M | $-4.1M | ||
| Q3 25 | $-18.7M | $4.0M | ||
| Q2 25 | $-18.3M | $-2.9M | ||
| Q1 25 | $-22.6M | $-833.0K | ||
| Q4 24 | $-22.3M | — | ||
| Q3 24 | $-28.8M | $-2.4M | ||
| Q2 24 | $-22.7M | — | ||
| Q1 24 | $-31.2M | — |
| Q4 25 | -60.5% | — | ||
| Q3 25 | -121.6% | — | ||
| Q2 25 | -103.2% | — | ||
| Q1 25 | -164.3% | — | ||
| Q4 24 | -138.8% | — | ||
| Q3 24 | -204.4% | — | ||
| Q2 24 | -134.6% | — | ||
| Q1 24 | -192.1% | — |
| Q4 25 | -64.1% | -24.9% | ||
| Q3 25 | -123.6% | 23.9% | ||
| Q2 25 | -99.7% | -16.5% | ||
| Q1 25 | -151.7% | -5.1% | ||
| Q4 24 | -131.4% | — | ||
| Q3 24 | -197.3% | -16.7% | ||
| Q2 24 | -126.1% | — | ||
| Q1 24 | -182.7% | — |
| Q4 25 | $-0.42 | $-0.19 | ||
| Q3 25 | $-0.88 | $0.19 | ||
| Q2 25 | $-0.85 | $-0.16 | ||
| Q1 25 | $-1.06 | $-0.06 | ||
| Q4 24 | $-1.05 | — | ||
| Q3 24 | $-1.36 | — | ||
| Q2 24 | $-1.07 | — | ||
| Q1 24 | $-1.47 | — |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $37.4M | $13.5M |
| Total DebtLower is stronger | — | $314.3M |
| Stockholders' EquityBook value | $126.6M | $391.2M |
| Total Assets | $329.5M | $854.4M |
| Debt / EquityLower = less leverage | — | 0.80× |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $37.4M | $13.5M | ||
| Q3 25 | $32.3M | $19.6M | ||
| Q2 25 | $44.8M | $8.4M | ||
| Q1 25 | $60.2M | $3.3M | ||
| Q4 24 | $84.3M | — | ||
| Q3 24 | $37.2M | — | ||
| Q2 24 | $35.8M | — | ||
| Q1 24 | $63.5M | — |
| Q4 25 | — | $314.3M | ||
| Q3 25 | — | $307.1M | ||
| Q2 25 | — | $316.9M | ||
| Q1 25 | — | $310.2M | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
| Q4 25 | $126.6M | $391.2M | ||
| Q3 25 | $64.7M | $385.2M | ||
| Q2 25 | $79.3M | $369.9M | ||
| Q1 25 | $93.5M | $324.7M | ||
| Q4 24 | $111.8M | — | ||
| Q3 24 | $128.8M | $1.0K | ||
| Q2 24 | $148.9M | — | ||
| Q1 24 | $166.1M | — |
| Q4 25 | $329.5M | $854.4M | ||
| Q3 25 | $280.7M | $846.8M | ||
| Q2 25 | $301.0M | $856.5M | ||
| Q1 25 | $323.0M | $860.8M | ||
| Q4 24 | $348.6M | — | ||
| Q3 24 | $376.7M | $1.0K | ||
| Q2 24 | $398.8M | — | ||
| Q1 24 | $413.6M | — |
| Q4 25 | — | 0.80× | ||
| Q3 25 | — | 0.80× | ||
| Q2 25 | — | 0.86× | ||
| Q1 25 | — | 0.96× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-11.7M | $42.1M |
| Free Cash FlowOCF − Capex | $-11.8M | — |
| FCF MarginFCF / Revenue | -63.6% | — |
| Capex IntensityCapex / Revenue | 0.8% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-18.5M | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $-11.7M | $42.1M | ||
| Q3 25 | $-6.5M | $8.3M | ||
| Q2 25 | $17.5M | $9.3M | ||
| Q1 25 | $-13.5M | $8.1M | ||
| Q4 24 | $-16.8M | — | ||
| Q3 24 | $-10.4M | — | ||
| Q2 24 | $-14.8M | — | ||
| Q1 24 | $-28.6M | — |
| Q4 25 | $-11.8M | — | ||
| Q3 25 | $-7.9M | — | ||
| Q2 25 | $17.4M | — | ||
| Q1 25 | $-16.0M | — | ||
| Q4 24 | $-25.5M | — | ||
| Q3 24 | $-19.4M | — | ||
| Q2 24 | $-21.3M | — | ||
| Q1 24 | $-30.3M | — |
| Q4 25 | -63.6% | — | ||
| Q3 25 | -52.5% | — | ||
| Q2 25 | 94.7% | — | ||
| Q1 25 | -107.4% | — | ||
| Q4 24 | -150.6% | — | ||
| Q3 24 | -132.5% | — | ||
| Q2 24 | -118.6% | — | ||
| Q1 24 | -177.5% | — |
| Q4 25 | 0.8% | — | ||
| Q3 25 | 9.6% | — | ||
| Q2 25 | 0.8% | — | ||
| Q1 25 | 17.0% | — | ||
| Q4 24 | 51.6% | — | ||
| Q3 24 | 61.3% | — | ||
| Q2 24 | 36.4% | — | ||
| Q1 24 | 9.8% | — |
| Q4 25 | — | — | ||
| Q3 25 | — | 2.06× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | — | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — | ||
| Q1 24 | — | — |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
